Healx
Founded Year
2014Stage
Series C | AliveTotal Raised
$113.38MLast Raised
$47M | 2 mos agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+302 points in the past 30 days
About Healx
Healx is a technology company focused on artificial intelligence (AI) drug discovery for rare disease treatment within the pharmaceutical industry. The company specializes in using AI to identify drug-disease relationships and accelerate the development of new therapies for rare conditions. Healx's approach aims to increase the scale and success rate of rare disease treatment development by repurposing known compounds and running multiple drug discovery programs in parallel. Healx was formerly known as Healx3. It was founded in 2014 and is based in Cambridge, United Kingdom.
Loading...
ESPs containing Healx
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The protocol design & optimization tools market focuses on designing and planning clinical trials and research studies. This market offers a range of solutions to develop study protocols that adhere to ethical guidelines, regulatory requirements, and scientific rigor. By engaging in the clinical study & protocol design market, organizations and researchers can ensure that studies generate reliable…
Healx named as Leader among 15 other companies, including Medidata, TriNetX, and Verily.
Healx's Products & Differentiators
Indication expansion
New rare or common disease predictions for human safe compounds. Our technology can be applied to marketed, development or shelved compounds. Healx performs prediction and early pharmacological validation of predictions.
Loading...
Research containing Healx
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Healx in 2 CB Insights research briefs, most recently on Aug 21, 2024.
Aug 21, 2024
The clinical trials tech market mapMay 17, 2022 report
AI 100: The most promising artificial intelligence startups of 2022Expert Collections containing Healx
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Healx is included in 5 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
14,769 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health 50
150 items
The winners of the second annual CB Insights Digital Health 150.
Digital Health
11,068 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
AI 100
100 items
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Healx Patents
Healx has filed 11 patents.
The 3 most popular patent topics include:
- neurological disorders
- syndromes
- autism
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
4/12/2019 | 2/28/2023 | Phosphodiesterase inhibitors, Lactams, Amines, Beta blockers, Piperazines | Grant |
Application Date | 4/12/2019 |
---|---|
Grant Date | 2/28/2023 |
Title | |
Related Topics | Phosphodiesterase inhibitors, Lactams, Amines, Beta blockers, Piperazines |
Status | Grant |
Latest Healx News
Sep 6, 2024
Tech.eu Tech.eu Insights creates insight and guides strategies with its comprehensive content and reports. Browse popular Insights content. August 2024's top 10 European tech deals you need to know about August saw a significant slowdown in European tech funding, with €1.9 billion raised (down 60% from July’s €5 billion). Here is the list of the 10 largest deals of the month. August was the slowest month YTD, with over €1.9 billion raised in some 203 deals. This figure represents a decrease of around 60 per cent compared to the previous month (in July European tech companies collected €5 billion). The August slowdown within the European tech investment landscape commented Jasenko Hadzic , Principal at BackingMinds, in our August Tech.eu Pulse , a compact version of the monthly report: The summer months are notoriously hard to fundraise in - Nordic funds are off on holidays in July, whereas funds from UK and rest of Europe are out in August. The funding/exit data for August very much reflects this, making August the slowest month YTD. This is as expected and a cyclical trend in our industry. Looking ahead, I’m optimistic that Q3 will end on a high note and Q4 will reach pre-summer levels. With central banks all of the world cutting interest rates, inflation numbers should come down, making investors unload some of that dry-powder and activity to pick up even more. For his more detailed review as well as more in-depth analyses of the European tech ecosystem, including industry and country performance, exit activities and more, check out our August report . And here is the list of 10 biggest European tech deals in August which collected together around 60 per cent of the total amount collected this month. 1 Sunly is a renewable energy company focused on developing and managing sustainable energy projects. Established to promote clean energy, Sunly invests in and operates wind, solar, and energy storage solutions across various regions. The company's mission is to support the transition to a low-carbon future by providing environmentally friendly and economically viable energy alternatives. Recently, Sunly has raised €300 million in debt financing to accelerate the construction of 1.3 GW of solar, wind, storage, and hybrid parks across the Baltics and Poland. 2 Powerdot is a company specializing in electric vehicle (EV) charging infrastructure. Founded to support the growing demand for sustainable transportation, Powerdot develops and operates a network of EV charging stations across Portugal and other European markets. The company focuses on providing convenient, reliable, and accessible charging solutions for both public and private sectors. The company has raised €165 million in green financing to scale its ultra-fast power charging points. 3 Caresyntax is a technology company that specializes in improving surgical care through data-driven solutions. Founded to enhance the safety, efficiency, and outcomes of surgical procedures, Caresyntax provides a platform that integrates data analytics, AI, and digital tools to support surgical teams. The company's platform is used to manage and analyze data from surgeries in real-time, offering insights that help reduce risks, streamline workflows, and improve patient outcomes. In their latest funding round, Caresyntax raised $180 million for AI surgery platform. 4 The company offers cloud-based software that manages payroll processes, compliance, and payments for multinational organizations. With a focus on simplifying and automating payroll management, CloudPay enables companies to handle complex payroll operations across multiple countries, ensuring accuracy, compliance with local regulations, and timely payments. The company has raised $120 million in a new funding round, which will enable it to enhance its customer products and technology solutions. 5 Yodel is a delivery and logistics company that specializes in parcel distribution services. Catering to a wide range of businesses, from small online retailers to large e-commerce platforms, Yodel offers nationwide coverage for parcel delivery across the United Kingdom. The company provides various delivery options, including next-day and two-day services, with a focus on flexibility and customer satisfaction. The company has secured a €99 million funding package that will enable them to invest in plans to further automate and modernise their business over the next three years. 6 Riverlane (UK) Riverlane is a quantum computing company that focuses on developing software to harness the power of quantum computers for practical applications. The company creates tools and operating systems that enable quantum computers to solve complex problems in industries such as chemistry, materials science, and pharmaceuticals. Riverlane works closely with hardware manufacturers, researchers, and industry partners to bridge the gap between quantum theory and real-world applications. The company’s mission is to accelerate the development of quantum computing technology, making it accessible and impactful for solving some of the world's most challenging computational problems. Recently, the company raised $75 million Series C for quantum error correction technology. 7 Oxford Nanopore Technologies (UK) Oxford Nanopore Technologies is a biotechnology company that specializes in developing and commercializing innovative sequencing technologies. Oxford Nanopore's technology allows for the direct analysis of long molecules, enabling comprehensive and detailed genetic insights that are crucial for advancing scientific understanding and improving healthcare outcomes. In their recent round, the company has secured £50 million in investment. 8 Morpho is a technology company focused on developing decentralized finance (DeFi) solutions. It offers a peer-to-peer protocol that enhances the efficiency of lending and borrowing in decentralized financial markets. The company offers an open, efficient, and resilient platform where users can earn yield and borrow assets. Additionally, developers and businesses can utilize its flexible, permissionless infrastructure to create markets, curate vaults, and build diverse applications. In August, Morpho has secured $50 million in fresh funding. This investment will enable the company to collaborate with industry leaders who share its vision of an open, layered financial system, fueling its growth and advancing its decentralization efforts. 9 Healx (UK) Healx is a pioneering biotechnology company focused on accelerating drug discovery and development for rare diseases. Utilizing advanced AI and machine learning technologies, Healx aims to identify and develop novel treatments by analyzing complex biological data and existing drug information. Their innovative approach seeks to streamline the drug discovery process, making it faster and more efficient, with the ultimate goal of bringing life-changing therapies to patients in need. Recently, the company has raised $47 million in a Series C round. 10 MYNE (Germany) MYNE is a vacation property technology company that focuses on optimizing and streamlining the management of vacation rentals. By leveraging advanced technology, MYNE aims to enhance the overall guest experience and operational efficiency for property owners. Their innovative solutions are designed to address common challenges in the vacation rental market, making it easier for both property managers and travelers to connect and engage. The company recently raised $40 million in funding to further develop its technology and financing platform and expand its portfolio in existing markets. 1/10
Healx Frequently Asked Questions (FAQ)
When was Healx founded?
Healx was founded in 2014.
Where is Healx's headquarters?
Healx's headquarters is located at 66-68 Hills Road, Cambridge.
What is Healx's latest funding round?
Healx's latest funding round is Series C.
How much did Healx raise?
Healx raised a total of $113.38M.
Who are the investors of Healx?
Investors of Healx include Jonathan Milner, Balderton Capital, b2venture, Global Brain, Atomico and 11 more.
Who are Healx's competitors?
Competitors of Healx include Aitia, Verge Genomics, Cyclica, BERG, BenevolentAI and 7 more.
What products does Healx offer?
Healx's products include Indication expansion and 3 more.
Who are Healx's customers?
Customers of Healx include Ovid Therapeutics.
Loading...
Compare Healx to Competitors
Aitia is a company focused on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. These Digital Twins are used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.
Insitro focuses on drug discovery and development. The company's main services involve the use of machine learning and high-throughput biology to predict successful paths for medicine creation. It aims to avoid costly failures in pharmaceutical research and development (R&D). Insitro primarily sells to the healthcare industry. It was founded in 2018 and is based in South San Francisco, California.
Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)--based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
Aria Pharmaceuticals operates as a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small-molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using its proprietary symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.
Standigm is an AI-driven drug discovery company operating in the pharmaceutical industry. The company's main services include the use of proprietary AI platforms for novel target identification, lead generation, and the creation of commercially valuable drug pipelines. Standigm primarily sells to the pharmaceutical and healthcare industries. It was founded in 2015 and is based in Seoul, South Korea.
BioMap focuses on leveraging artificial intelligence (AI) to advance life sciences. The company develops AI Foundation Models to understand and predict biological behaviors and creates task models for various life science applications, including therapeutic antibodies and industrial enzymes. BioMap primarily serves the biotechnology and pharmaceutical industries with its AI-driven solutions. It was founded in 2020 and is based in Palo Alto, California.
Loading...